5 Stocks Pushing The Health Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 23 points (-0.2%) at 13,146 as of Friday, Dec. 14, 2012, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,344 issues advancing vs. 1,517 declining with 152 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Centene Corporation ( CNC), down 8.5%, WellCare Health Plans ( WCG), down 5.9%, Molina Healthcare ( MOH), down 4.3% and Life Technologies ( LIFE), down 1.4%. Top gainers within the industry include Community Health Systems ( CYH), up 1.6%, ResMed ( RMD), up 1.0% and Quest Diagnostics ( DGX), up 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Thermo Fisher Scientific ( TMO) is one of the companies pushing the Health Services industry lower today. As of noon trading, Thermo Fisher Scientific is down $0.38 (-0.6%) to $64.54 on average volume Thus far, 879,801 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $64.49-$64.85 after having opened the day at $64.80 as compared to the previous trading day's close of $64.92.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $23.5 billion and is part of the health care sector. The company has a P/E ratio of 20.8, above the S&P 500 P/E ratio of 17.7. Shares are up 44.9% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Thermo Fisher Scientific Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

4. As of noon trading, Cigna ( CI) is down $0.75 (-1.4%) to $52.95 on light volume Thus far, 682,483 shares of Cigna exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $52.88-$53.58 after having opened the day at $53.43 as compared to the previous trading day's close of $53.70.

CIGNA Corporation, a health services organization, through its subsidiaries, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $15.4 billion and is part of the health care sector. The company has a P/E ratio of 10.0, below the S&P 500 P/E ratio of 17.7. Shares are up 27.9% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Cigna a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Cigna Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

3. As of noon trading, Humana ( HUM) is down $0.87 (-1.3%) to $66.00 on light volume Thus far, 350,912 shares of Humana exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $65.78-$66.79 after having opened the day at $65.85 as compared to the previous trading day's close of $66.87.

Humana Inc. operates as a health care company that offers a range of insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. Humana has a market cap of $10.7 billion and is part of the health care sector. The company has a P/E ratio of 9.0, below the S&P 500 P/E ratio of 17.7. Shares are down 22.8% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Humana a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Humana Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

2. As of noon trading, WellPoint ( WLP) is down $0.55 (-0.9%) to $58.47 on light volume Thus far, 902,204 shares of WellPoint exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $58.02-$58.96 after having opened the day at $58.39 as compared to the previous trading day's close of $59.02.

WellPoint, Inc., through its subsidiaries, operates as a health benefits company in the United States. The company offers various network-based managed care plans to large and small employer, individual, Medicaid, and senior markets. WellPoint has a market cap of $18.0 billion and is part of the health care sector. The company has a P/E ratio of 7.8, below the S&P 500 P/E ratio of 17.7. Shares are down 10.6% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate WellPoint a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates WellPoint as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full WellPoint Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

1. As of noon trading, Aetna ( AET) is down $0.34 (-0.7%) to $45.63 on average volume Thus far, 1.8 million shares of Aetna exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $45.34-$45.99 after having opened the day at $45.34 as compared to the previous trading day's close of $45.97.

Aetna Inc. operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. Aetna has a market cap of $15.4 billion and is part of the health care sector. The company has a P/E ratio of 8.7, below the S&P 500 P/E ratio of 17.7. Shares are up 8.8% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Aetna a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Aetna as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, increase in net income, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Aetna Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

If you liked this article you might like

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Big Pharma and the Sellers of Its Products Now Have a Problem

Big Pharma and the Sellers of Its Products Now Have a Problem

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Jim Cramer: The 3 Best Sectors That Lifted the Stock Market

Cramer: Lessons From the Market and ICR

Cramer: Lessons From the Market and ICR